Phone +91-8455-699999
Brochure Corporate Brochure | Fosun Pharma
Search
Menu

STOCK EXCHANGE ANNOUNCEMENTS

Date Title
December 03, 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    November 25, 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    November 08, 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    November 06, 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    October 22, 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    September 16, 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    September 12, 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    September 11, 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    September 09, 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    August 30, 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    August 26, 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meeting
    		•
    August 16, 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    August 8, 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meeting
    		•
    July 19, 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    June 7 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    June 3 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    May 27 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    May 21 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    May 09 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    March 26 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    March 19 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    March 14 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    March 11 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    March 07 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    March 04 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    Fabruary 19 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    Fabruary 13 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    January 18 2024
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    December 7 2023
  • Intimation of Schedule of Analyst/ Institutional Investor Meetings.
    		•
    December 5 2023
  • Intimation of Schedule of Analyst/ Institutional Investor Meetings.
    		•
    November 22 2023
  • Intimation of Schedule of Analyst/ Institutional Investor Meetings.
    		•
    November 18 2023
  • Intimation of Schedule of Analyst/ Institutional Investor Meetings.
    		•
    November 14 2023
  • Intimation of Schedule of Analyst/ Institutional Investor Meetings.
    		•
    November 07 2023
  • Intimation of Schedule of Analyst/ Institutional Investor Meetings.
    		•
    September 25, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    September 20, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    September 20, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    September 19, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    • September 18, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    • September 14, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    • September 12, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    • September 12, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    September 01, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    August 23, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    August 22, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    June 12, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    June 1, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    May 29, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    May 25, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    May 24, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    May 23, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    May 03, 2023
  • Earnings Conference Call – Q4FY23
    		•
    March 21, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    March 17, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    March 13, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    March 06, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    March 01, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    Februrary 27, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    Februrary 24, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    Februrary 23, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    Februrary 10, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    Februrary 07, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    Februrary 06, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    January 31, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    January 27, 2023
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    January 06, 2023
  • earnings Call Intimation
    		•
    December 26, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    December 15, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    December 12, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    December 07, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    December 05, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    December 01, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    November 24, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    November 21, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    November 14, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    November 10, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    November 09, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    November 07, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    November 01, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    October 28, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    October 10, 2022
  • Earnings Conference call Intimation.
    • September 20, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    September 12, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    September 06, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    September 09, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    September 06, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    August 30, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    August 26, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    August 16, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    August 10, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    August 04, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    August 03, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    July 28, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    July 27, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    July 25, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    July 05, 2022
  • Earnings Call intimation
    		•
    June 27, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    June 17, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    June 13, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    June 08, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    June 06, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    May 30, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings.
    		•
    May 25, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    May 20, 2022
  • Intimation of Audio recording of Earnings Call for the quarter and year ended March 31, 2022
    		•
    May 20, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    May 04, 2022
  • Earnings Call intimation
    		•
    April 05, 2022
  • Intimation of Earnings Conference Call Q4FY2022
    		•
    March 31, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    March 28, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    March 23, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    March 22, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    March 21, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    March 11, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    March 09, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    March 08, 2022
    March 07, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    February 25, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    February 21, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    February 16, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    January 24, 2022
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    January 03, 2022
  • Earnings Call intimation
    		•
    December 21, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    December 21, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    December 16, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    December 15, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    December 8, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    December 1, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    November 30, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    November 23, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    November 22, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    November 16, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    November 8, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    November 3, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    October 26, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    October 26, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    October 22, 2021
  • Invester Presentation on the Financial Results
    		•
    October 22, 2021
  • Press Release on the Financial Results
    • October 5, 2021
  • Earnings Call intimation
    		•
    September 27, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    September 23, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    September 21, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    September 21, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    September 16, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    September 11, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    September 7, 2021
  • Investor Presentation : Motilal Oswal 17th Annual Global Investor Conference
    		•
    September 6, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    September 3, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    August 16, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    August 9, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    July 29, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    July 28, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    July 26, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    July 05, 2021
  • Earnings Conference Call
    		•
    June 28, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    June 28, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    June 22, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    June 19, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    June 11, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    June 7, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    May 29, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    May 29, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    May 25, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    May 24, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    May 21, 2021
  • Intimation on Earnings Call Transcript- Q4FY21
    		•
    May 20, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    May 17, 2021
  • Earnings Call audio Intimation
    		•
    April 12, 2021
  • Earnings Conference Call Intimation
    		•
    March 29, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    March 12, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    March 5, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    February 25, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    February 23, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    February 18, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    February 15, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    February 11, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    February 10, 2021
  • Intimation on Earnings Call Transcript
    • February 10, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    February 9, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    February 6, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    February 5, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    February 4, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    February 2, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    February 2, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    January 29, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    January 28, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    January 23, 2021
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    January 12, 2021
  • Earnings Call intimation
    		•
    December 25, 2020
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    December 22, 2020
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    December 17, 2020
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    December 16, 2020
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    December 15, 2020
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    December 14, 2020
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    December 8, 2020
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    November 25, 2020
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•
    November 21, 2020
  • Intimation of Schedule of Analyst / Institutional Investor Meetings
    		•

    Date Title
    December 03, 2024
  • Resignation of Mr. Ankit Gupta
    • December 03, 2024
  • Press Release: Gland Pharma receives approval for Latanoprost Ophthalmic Solution
    • November 04, 2024
  • Earnings Call Recording
    • November 04, 2024
  • Outcome of the Board Meeting
    • October 18, 2024
  • Appointment of Chief Executive Officer
    • October 16, 2024
  • Certificate under Regulation 74(5) of the SEBI (Depository and Participants Regulations), 2018
    • September 30, 2024
  • Intimation regarding trading window closure for quarter and half year ended 30th September 2024
    • September 10, 2024
  • Changes(s) in Directorate
    • August 30, 2024
  • Change(s) in Directorate
    • August 26, 2024
  • Intimation to shareholders regarding Notice of 46th Annual General Meeting
    • August 12, 2024
  • Earnings call Transcript- Q1FY25
    • August 12, 2024
  • : Change(s) in Senior Management Personnel (“SMP”)
    		•
    August 6, 2024
  • Earnings Call Recording
    		•
    August 6, 2024
  • Disclosure under Regulation 30 read with Schedule III Para A Sub Para 20 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
    		•
    August 6, 2024
  • Conclusion of US FDA Un-announced Inspection at Pashamylaram Facility, Hyderabad
    		•
    August 2, 2024
  • Conclusion of US FDA Un-announced Inspection at Pashamylaram Facility, Hyderabad
    		•
    July 25 2024
  • Conclusion of US FDA Surprise Inspection at Dundigal Facility, Hyderabad
    		•
    July 23 2024
  • Press Release: Gland Pharma receives Tentative Approval from the USFDA for Latanoprostene Bunod Ophthalmic Solution
    • July 15 2024
  • Certificate under Regulation 74(5) of the SEBI (Depository and Participants Regulations), 2018
    		•
    June 28 2024
  • Intimation regarding trading window closure for quarter ended 30th June 2024
    		•
    June 7 2024
  • Allotment of Equity Shares on exercise of ESOP
    		•
    June 7 2024
  • Outcome of the Board Meeting
    		•
    June 7 2024
  • Press Release: Srinivas Sadu appointed as Executive Chairman and CEO of Gland Pharma Limited
    		•
    May 31 2024
  • Change(s) in Senior Management Personnel (“SMP”)
    		•
    May 29 2024
  • Earnings call Transcript- Q4FY24
    		•
    May 24 2024
  • US FDA Inspection at JNPC Facility, Visakhapatnam
    		•
    May 23 2024
  • Outcome of the Board Meeting
    		•
    May 23 2024
  • Intimation regarding the Earnings Call Q4FY24 Audio recording link
    		•
    May 07 2024
  • Press Release: Gland Pharma receives approval for Edaravone Injection
    		•
    May 07 2024
  • Press Release: Gland Pharma receives approval for Plerixafor for Injection
    		•
    April 29 2024
  • Outcome of the Board Meeting
    		•
    April 29 2024
  • Press Release: Gland Pharma receives approval for Cetrorelix Acetate for Injection
    		•
    April 17 2024
  • Certificate pursuant to Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended March 31, 2024.
    		•
    April 11 2024
  • Clarification regarding increase in volumes- your e-mail dated April 10, 2024.
    		•
    April 10 2024
  • Certificate under Regulation 74(5) of the SEBI (Depository and Participants Regulations), 2018.
    • April 10 2024
  • Certificate pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended March 31, 2024.
    		•
    April 8 2024
  • Press Release: Gland Pharma receives approval for Eribulin Mesylate Injection.
    		•
    March 26 2024
  • Intimation regarding trading window closure for quarter and financial year ended 31st March 2024.
    • March 26 2024
  • Change(s) in Senior Management Personnel.
    		•
    March 26 2024
  • Allotment of Equity Shares on exercise of ESOP.
    		•
    Fabruary 21 2024
  • Intimation regarding the Earnings Transcript Q3FY24 Audio recording link.
    		•
    Fabruary 15 2024
  • Intimation regarding the Earnings Call Q3FY24 Audio recording link.
    		•
    Fabruary 14 2024
  • Outcome of the Board Meeting.
    		•
    Fabruary 14 2024
  • Allotment of Equity Shares on exercise of ESOP.
    		•
    Fabruary 27 2024
  • Change of President for Cenexi.
    		•
    January 11 2024
  • Certificate under Regulation 74(5) of the SEBI (Depository and Participants Regulations), 2018.
    • December 29 2023
  • Intimation regarding trading window closure for quarter and nine months ended 31st December 2023.
    • November 24 2023
  • Receipt of EIR from US FDA for Pashamylaram Facility.
    		•
    November 20 2023
  • Outcome of postal ballot-reappointment of Independent Director.
    		•
    November 15 2023
  • Press Release-Tentative approval from USFDA for Angiotensin II for Injection.
    		•
    November 08 2023
  • Conclusion of US FDA Inspection at VSEZ Sterile Oncology Facility, Visakhapatnam.
    		•
    November 06 2023
  • Intimation regarding the Earnings Call Q2FY24 Audio recording link
    		•
    November 06 2023
  • Outcome of the Board Meeting
    		•
    October 17 2023
  • Intimation Reappointment of Mr. CSN Murty Independent Director of the Company.
    		•
    October 10 2023
  • Intimation regarding ESOP allotment.
    • September 29 2023
  • Intimation regarding trading window closure for quarter and half year ended 30th September 2023.
    • September 26 2023
  • Conclusion of US FDA Inspection at Pashamylaram Facility of the Company.
    		•
    September 19 2023
  • Intimation regarding appointment of President for Cenexi.
    		•
    September 04 2023
  • Intimation regarding Change of Senior Management Personnel.
    		•
    August 31, 2023
  • Intimation regarding appointment of Statutory Auditors.
    		•
    August 28, 2023
  • US FDA Inspection at Pashamylaram Facility, Hyderabad.
    		•
    August 25, 2023
  • Addendum to the Notice of the 45th AGM of the Company.
    		•
    August 23, 2023
  • Conclusion of US FDA Inspection at Dundigal Facility, Hyderabad.
    		•
    August 09, 2023
  • Clarofication to BSE in regard to increase in volume of shares.
    		•
    August 09, 2023
  • Business Responsibility and Sustainability Report for the financial year ended March 31, 2023.
    		•
    August 09, 2023
  • Notice of the 45th Annual General Meeting (AGM) along with copy of Annual Report for the year ended March 31, 2023
    		•
    August 08, 2023
  • Intimation regarding the Earnings Call Q1FY24 Audio recording link.
    		•
    August 07, 2023
  • Outcome Of Board Meeting_Q1FY2024
    		•
    July 28, 2023
  • Intimation regarding Earnings Conference Call - Q1FY24
    		•
    July 28, 2023
  • Announcement regarding US FDA Inspection at VSEZ Sterile Onclogy Facility
    		•
    July 14, 2023
  • Announcement regarding US FDA Inspection at Dundigal Facility
    		•
    July 12, 2023
  • Reply to Clarification Sought by BSE
    • July 10, 2023
  • Reply to Clarification sought by NSE
    • June 29, 2023
  • Intimation regarding Closure of Trading Window
    		•
    June 27, 2023
  • Intimation regarding USFDA Inspection at Pashamylaram Facility.
    		•
    May 18, 2023
  • Outcome of the Board Meeting.
    		•
    May 18, 2023
  • Intimation regarding Audio Recording of Earnings Conference Call Q4 FY 2022-23.
    		•
    April 27, 2023
  • Announcement regarding Completion of Acquisition of Cenexi.
    		•
    April 20, 2023
  • Clarification to BSE.
    		•
    April 20, 2023
  • Clarification to NSE.
    		•
    March 29, 2023
  • Intimation to Stock Exchanges Regarding ESOP Allotment.
    		•
    March 29, 2023
  • Intimation to Stock Exchanges Regarding Appointment of Statutory Auditors.
    		•
    March 24, 2023
  • Closure of Trading Window.
    		•
    February 04, 2023
  • Intimation to Stock Exchanges Regarding Notice of Postal Ballot.
    		•
    January 27, 2023
  • US FDA Inspection JNPC Facility.
    		•
    January 23, 2023
  • Link of Earning Call Recording for Q3FY23
    		•
    January 23, 2023
  • Outcome of the Board Meeting
    		•
    January 06, 2023
  • Update on proposed acquisition of Cenexi
    • January 04, 2023
  • Closure of US FDA Audit- Dundigal Facility
    		•
    December 30, 2022
  • Closure of Trading Window
    		•
    November 29, 2022
  • Clarification to Stock Exchanges.
    		•
    November 29, 2022
  • Intimation regarding Investor Call Recording
    		•
    November 29, 2022
  • Investors Call Recording
    		•
    November 29, 2022
  • Investor Presentation on the Proposed Acquisition of Cenexi Group
    		•
    November 29, 2022
  • Disclosure regarding the Proposed Acquisition of Cenexi Group
    		•
    November 29, 2022
  • Press Release on the Proposed Acquisition of Cenexi Group.
    		•
    November 24, 2022
  • ESOP Allotment.
    		•
    November 04, 2022
  • Related Party Transactions for the half year ended 30th September 2022
    		•
    October 26, 2022
  • Intimation of Earnings Call Recording Q2FY23
    		•
    October 26, 2022
  • Outcome of Board Meeting
    		•
    October 10, 2022
  • Board Meeting Intimation
    		•
    September 30, 2022
  • Closure of Trading Window
    		•
    September 15, 2022
  • ESOP Allotment.
    		•
    September 01, 2022
  • Disclosure regarding Retirement of Directors by rotation.
    		•
    August 26, 2022
  • Intimation Regarding Notice for 44thAGM
    		•
    August 25, 2022
  • Update on US FDA InspectionthAGM
    		•
    August 08, 2022
  • Newspaper Advertisement regarding Notice of the 44thAGM
    		•
    August 05, 2022
  • Notice of 44thAGM
    		•
    August 05, 2022
  • Newspaper Advertisement before dispatch of Notice of AGM
    		•
    July 22, 2022
  • Advertisement on the Unaudited Financial Results for the Quarter ended June 30, 2022
    		•
    July 20, 2022
  • Intimation of Earnings Cal Recording Q1FY23
    		•
    July 20, 2022
  • Outcome of the Board Meeting.
    		•
    July 04, 2022
  • Board Meeting Intimation.
    		•
    June 30, 2022
  • Closure of Trading Window.
    		•
    June 15, 2022
  • ESOP Allotment.
    		•
    May 31, 2022
  • Related Party Transactions for the half year ended 31st March 2022.
    		•
    May 20, 2022
  • Advertisement on the Audited Financial Results for the Quarter and Financial Year ended March 31, 2022
    		•
    May 19, 2022
  • Outcome of the Board meeting Q4FY22
    		•
    May 04, 2022
  • Press Release-Launch of Bortezomib for Injection through our partner in the US Market
    		•
    April 29, 2022
  • ESOP Allotment
    		•
    April 04, 2022
  • Board Meeting Intimation
    		•
    March 31, 2022
  • Closure of Trading Window
    		•
    March 22, 2022
  • Newspaper Advertisement for Postal Ballot
    		•
    March 21, 2022
  • Intimation of Postal Ballot Notice
    		•
    March 16, 2022
  • Newspaper Advertisement for Registration of e-mail address
    		•
    March 10, 2022
  • Outcome of the Board Meeting- Appointment and Resignation of Directors
    		•
    January 22, 2022
  • Advertisement on the Unaudited Financial Results for the Quarter and Nine months ended December 31, 2021
    		•
    January 21, 2022
  • Outcome Of The Board Meeting
    		•
    December 28, 2021
  • Board Meeting Intimation
    		•
    December 21, 2021
  • ESOP Allotment
    		•
    December 08, 2021
  • Press Release-Product tentative approval-Cangrelor for Injection
    		•
    October 30, 2021
  • Intimation of Related Party filing delay for half year ending March 31, 2021
    		•
    October 23, 2021
  • Advertisement on the Unaudited Financial Results for the Quarter and Half year ended September 30, 2021
    		•
    October 22, 2021
  • Outcome of the Board Meeting
    		•
    October 08, 2021
  • Press Release- Product Tentative approval for Sugammadex Injection, 200
    • October 7, 2021
  • ESOP Allotment
    		•
    September 30, 2021
  • Board Meeting Intimation Advertisement
    • September 29, 2021
  • Board Meeting Intimation
    		•
    August 27, 2021
  • Voting Result and Combined Scrutinizer’s Report of the 43rd AGM
    		•
    August 27, 2021
  • 43rd AGM Proceedings
    		•
    August 04, 2021
  • Book Closure Intimation
    		•
    August 04, 2021
  • Notice of AGM Newspaper advertisement
    • July 22, 2021
  • Advertisement on the Unaudited Financial Results for the Quarter ended June 30, 2021
    		•
    July 21, 2021
  • Intimation of Monitoring agency report
    • July 21, 2021
  • Outcome of the Board Meeting
    		•
    July 15, 2021
  • Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018
    		•
    June 29, 2021
  • Board Meeting intimation advertisement for the Quarter ended June 30, 2021
    		•
    June 28, 2021
  • Board Meeting intimation for the Quarter ended June 30, 2021
    		•
    June 19, 2021
  • Related Party Transactions for the half Year ended March 31, 2021
    		•
    May 18, 2021
  • Newspaper publication on Q4FY21 Results
    • May 17, 2021
  • Outcome of the Board Meeting
    		•
    May 12, 2021
  • Intimation of Monitoring Agency Report-Q4FY21
    		•
    May 5, 2021
  • Intimation of ESOP Allotment
    		•
    April 22, 2021
  • Product Approval
    		•
    April 8, 2021
  • Disclosure pursuant to SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144
    		•
    April 5, 2021
  • Intimation of newspaper publication on Board Meeting
    		•
    April 3, 2021
  • Intimation of Board Meeting
    		•
    March 16, 2021
  • Intimation of ESOP Allotment
    		•
    March 16, 2021
  • Intimation under Regulation 30
    		•
    December 31, 2020
  • Intimation of Board Meeting
    		•
    January 23, 2021
  • Intimation of Newspaper advertisement pertaining to Unaudited Financial Results of Q3 FY 2021
    • January 22, 2021
  • Intimation of ESOP Allotment
    		•
    January 22, 2021
  • Outcome of the Board Meeting
    		•
    January 22, 2021
  • Intimation of Monitoring Agency Report-Q3FY21
    		•
    January 1, 2021
  • Intimation of Board Meeting- Advertisement
    		•

    Date Title
    November 11 2024
  • Newspaper Publication
    		•
    November 05 2024
  • Newspaper Publication
    		•
    October 27 2024
  • Notice for attention of members of Gland Pharma Limited
    		•
    August 27 2024
  • Newspaper Advertisement - Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
    		•
    August 08 2024
  • Newspaper Advertisement - Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
    		•
    August 01 2024
  • Newspaper Advertisement - Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
    		•
    May 23, 2024
  • Newspaper Publication
    		•
    May 23, 2024
  • Newspaper Publication
    		•
    Fabruary 15, 2024
  • Newspaper Publication
    		•
    November 07, 2023
  • Newspaper Publication regarding Unaudited Financial Results for the quarter ended September 30, 2023
    		•
    October 20, 2023
  • Newspaper Publication regarding Dispatch of Postal Ballot Notice.
    		•
    October 18, 2023
  • Newspaper Publication regarding Email Updation.
    		•
    August 28, 2023
  • Newspaper Publication regarding addendum.
    		•
    August 10, 2023
  • Newspaper Publication regarding Notice of 45th Annual General Meeting
    		•
    August 08, 2023
  • Newspaper Publication regarding Unaudited Financial Results for the quarter ended June 30, 2023
    • August 07, 2023
  • Newspaper Publication regarding AGM
    		•
    May 19, 2023
  • Newspaper advertisement pertaining to Unaudited Financial Results of Q4FY2023
    		•
    February 05, 2023
  • Newspaper advertisement regarding dispatch of Notice of Postal Ballot
    		•
    February 03, 2023
  • Newspaper advertisement for Updation of Email address of Members
    		•
    January 24, 2023
  • Newspaper advertisement pertaining to Unaudited Financial Results of Q3FY2023
    		•
    October 27, 2022
  • Newspaper advertisement pertaining to Unaudited Financial Results of Q2FY23
    		•
    August 27, 2022
  • Newspaper Advertisement regarding 44th AGM
    		•
    August 08, 2022
  • Newspaper Advertisement-Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
    		•
    August 05, 2022
  • Newspaper Advertisement-Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
    		•
    July 21, 2022
  • Newspaper advertisement pertaining to Unaudited Financial Results of Q1FY2023
    		•
    May 20, 2022
  • Newspaper advertisement pertaining to Audited Financial Results of Q4 FY 2022
    		•
    March 22, 2022
  • Notice of Postal Ballot - Advertisement.
    • March 16, 2022
  • Newspaper advertisement for registration of e-mail address of Members.
    		•
    January 22, 2022
  • Newspaper advertisement pertaining to Unaudited Financial Results of Q3 FY 2022
    		•
    October 22, 2021
  • Newspaper advertisement pertaining to Unaudited Financial Results of Q2 FY 2022
    		•
    September 30, 2021
  • Notice of Board Meeting - Advertisement
    • July 22, 2021
  • Newspaper advertisement pertaining to Unaudited Financial Results of Q1 FY 2022
    		•
    June 29, 2021
  • Notice of Board Meeting - Advertisement
    • May 18, 2021
  • Newspaper advertisement pertaining to Audited Financial Results of Q4 FY 2021
    		•
    April 05, 2021
  • Notice of Board Meeting - Advertisement
    • January 23, 2021
  • Newspaper advertisement pertaining to Unaudited Financial Results of Q3 FY 2021
    		•
    January 01, 2021
  • Notice of Board Meeting - Advertisement

    • About Us

    Our Capabilities

    Our Business

    Investors

    Resources

    CSR

    Contact Us

    PHONE:+91-40-30510999 | +91-8455-699999 | +91-7075736524 | EMAIL: GLAND@GLANDPHARMA.COM

    Site Map

    © Copyright 2024 Gland Pharma Limited